Chronic myeloid leukemia in the Asia-Pacific region: Current practice, challenges and opportunities in the targeted therapy era
Introduction
Chronic myeloid leukemia (CML) is a commonly diagnosed hematologic malignancy in Asia, and appears to have lower median age of onset in Asians than Caucasians [1]. In 2001, the introduction of the first targeted tyrosine kinase inhibitor (TKI), imatinib mesylate (Glivec®; Novartis) revolutionized the therapeutic paradigm and dramatically improved outcomes [2], [3]. Since then, international guidelines that recommend imatinib as first-line therapy for patients at all phases of CML, including those eligible for HSCT [4], [5], [6], [7], have been followed in principle by most countries throughout the Asia-Pacific region. However, wide regional variations in levels of economic development, differences in national healthcare systems and insurance coverage, and disparities in affluence, both within and between countries, have a major influence on individual clinicians’ approaches to CML management in everyday practice, and for these reasons, the CML management algorithm is not uniform across the Asia-Pacific region.
As second-generation TKIs are incorporated into clinical practice, the optimization of CML management for Asian patients has become an even higher priority. For these reasons, the Asia CML Study Alliance (ACSA) developed a comprehensive survey to assess current CML treatment patterns in the Asia-Pacific region in order to identify both knowledge gaps and unmet treatment needs that should be addressed to harmonize the treatment algorithm, as well as opportunities for research to address topics of particular relevance in the region.
Section snippets
ACSA Asia-Pacific CML survey
ACSA designed a questionnaire to survey CML treatment provision and patterns of CML management practice in Asia. Between November 2008 and April 2009, the questionnaire was distributed to specialist physicians treating CML patients at 33 different hospitals in countries/regions across the Asia-Pacific region (Appendix Table A.1).
The survey included both nation-specific questions on insurance coverage of CML therapies and CML research activities, for example, existence of study groups and CML
Survey participants
Respondents from 33 hospitals located in 14 Asia-Pacific countries/regions participated in the ACSA CML survey: Australia (2); China (7); Hong Kong (2); India (2); Indonesia (1); Japan (4); Malaysia (2); New Zealand (1); Philippines (1); Singapore (2); South Korea (1); Taiwan (5); Thailand (2); Vietnam (1). Their main departmental specialties included hematology (7), hematology and HSCT (8), hematology and oncology (14) and medical oncology (4).
Twenty respondents worked exclusively in an
Discussion
This survey of 33 centers across 14 countries/regions provides important insights into current clinical practice in the Asia-Pacific region, and serves as a baseline for future reference to gauge how CML management in the region has progressed or changed.
In considering these findings, we acknowledge certain limitations. The sample was relatively small, and included only one or a few major representative centers in each country. Furthermore, participants were selected because of their active
Conflict of interest
DWK, UB, YTG, PG, HH, SJ, LPK, SCN, JLT are members of Novartis Asia-Pacific CML Advisory Board and have received funding from Novartis for participation in research and clinical trials. II, TN, VP, HR, AT, JW and RW are members of Novartis Asia-Pacific CML Advisory Board. LYS received funding from Novartis for molecular analysis.
Acknowledgements
This work was supported by an unrestricted educational grant from Novartis.
The study sponsor provided advice and feedback on the survey questionnaire. The study sponsor had no involvement in the collection, analysis or interpretation of data. The study sponsor reviewed early drafts of the manuscript and supported the decision publish; however, the authors had complete independence in drafting and approving the final version and in their choice of journal for submission.
The authors would like to
References (23)
- et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood
(2006) - et al.
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
Blood
(2006) - et al.
Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years
Blood
(2007) - et al.
Chronic myeloid leukemia in Asia
Int J Hematol
(2009) - et al.
Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
N Engl J Med
(2003) - Guilhot F, Larson R, O’Brien S, Druker B, on behalf of IRIS Study Group. Long-term benefits of imatinib for patients...
- et al.
Recommendations of the Canadian consensus group on the management of chronic myeloid leukemia
Curr Oncol
(2006) Chronic myelogenous leukemia. Version 2
(2007)- Grigg A, Hughes T; for the Australasian Leukemia and Lymphoma Group (ALLG) Myoproliferative Disease Subcommittee....
- et al.
The biology of chronic myeloid leukemia
N Engl J Med
(1999)
Therapy with imatinib for chronic myeloid leukaemia
Ind J Med Paediatr Oncol
Cited by (36)
Classic myeloproliferative neoplasms in Singapore: A population-based study on incidence, trends, and survival from 1968 to 2017
2022, Cancer EpidemiologyCitation Excerpt :Good healthcare access might also partly explain this, as Singapore is a city-state without a rural population and with efficient transport system linking hospitals to major housing estates. Healthcare is also partially subsidised by the government [30]. Interestingly, we noted lower RSR in women compared to men, despite higher median survival, similar to a Lithuanian study (5-year RSR: 51% in male vs. 48% in female) [23].
Practical barriers to implementation of thyroid cancer guidelines in the Asia-pacific region
2015, Endocrine PracticeCost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand
2014, Clinical TherapeuticsCitation Excerpt :Unfortunately, no patients with BP-CML were identified during the data-collection period. Prior studies in other settings have reported that utilities in patients with BP-CML were lower than those in patients with AP-CML by ~0.2.4,8 On the basis of this, we assumed that the utility score of patients with BP-CML would be 0.31 (Table I).
Asia-Pacific Leukemia Consortium: An innovative and collaborative initiative to improve care of leukemia and related diseases in the Asia-Pacific region
2023, Asia-Pacific Journal of Clinical OncologyLong-Term Outcomes with Sequential Tyrosine Kinase Inhibitors Treatment in Chronic Myeloid Leukemia Patients
2023, Asian Pacific Journal of Cancer PreventionInequality in Drug Utilization among Chronic Myeloid Leukaemia Patients in Malaysia: A Cost,Utility Analysis
2022, Asian Pacific Journal of Cancer Prevention